Janelle Butters
Family · Sacramento, CANPI 1609383827
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Biogen at 59.5% of the total. Reporting peaked in 2021 at $4,007 and has fallen 88.6% since, to $455 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $205.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$3K
- Amgen$739
- E.r. Squibb & Sons, L.L.C.$510
- AstraZeneca$392
- Novartis$336
- AbbVie$125
- plus $231 from 2 others
What the payments were for
- Consulting fees$99317%
- Speaking & faculty fees$2,63046%
- Food & beverage$2,13137%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 8 | $3,421 |
| Amgen(2 entities) | 7 | $739 |
| E.r. Squibb & Sons, L.L.C. | 1 | $510 |
| AstraZeneca | 5 | $392 |
| Novartis | 4 | $336 |
| AbbVie | 1 | $125 |
| EMD Serono, Inc. | 1 | $123 |
| TG Therapeutics, Inc. | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,753 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Modafinil | 55 | $2,711 |
| Baclofen | 63 | $2,461 |
| Pregabalin | 56 | $2,008 |
| Gabapentin | 62 | $1,938 |
Paid to pharmacies, not to this prescriber.
Other family in Sacramento
- Kim SchaferSacramento$288K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.